Even though in gliomas mutations in IDH1 and IDH2 genes are usually heterozygous, homozygous ones also exist. IDH1/IDH2 aberrations, but not the ones in TP53, together with age might be applied in clinical practice for prediction of survival in patients with glioblastomas. This evidence concerns the gene IDH1 and glioblastoma.